Literature DB >> 10336685

Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms.

E Bezard1, T Boraud, B Bioulac, C E Gross.   

Abstract

The purpose of the present study was to investigate whether the subthalamic nucleus (STN) was implicated in the glutamatergic compensatory mechanisms which have been shown to mask the parkinsonian motor abnormalities at the end of the presymptomatic period in experimental parkinsonism. Using multiunit electrophysiological recordings, we follow changes of activity occurring in the STN and in both the pars externalis and the pars internalis of the globus pallidus of monkeys chronically intoxicated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), according to a protocol designed to mimic the gradual evolution of dopaminergic neuronal death. STN activity augmented significantly in the course of treatment, even before the first appearance of clinical signs (P < 0.01). This result would indicate that the STN, which increases its level of activity even before the end of the presymptomatic period, is principally responsible for the instigation of glutamatergic compensatory mechanisms which allow the maintenance of the striatal dopaminergic homeostasis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10336685     DOI: 10.1046/j.1460-9568.1999.00627.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  22 in total

1.  Distinct roles for nigral GABA and glutamate receptors in the regulation of dendritic dopamine release under normal conditions and in response to systemic haloperidol.

Authors:  William S Cobb; Elizabeth D Abercrombie
Journal:  J Neurosci       Date:  2002-02-15       Impact factor: 6.167

2.  Pre-synaptic dopaminergic compensation after moderate nigrostriatal damage in non-human primates.

Authors:  Xiomara A Perez; Neeraja Parameswaran; Luping Z Huang; Kathryn T O'Leary; Maryka Quik
Journal:  J Neurochem       Date:  2008-02-01       Impact factor: 5.372

3.  Neural responses in multiple basal ganglia regions following unilateral dopamine depletion in behaving rats performing a treadmill locomotion task.

Authors:  Jing-Yu Chang; Li-Hong Shi; Fei Luo; Donald J Woodward
Journal:  Exp Brain Res       Date:  2005-12-21       Impact factor: 1.972

4.  Localization and function of dopamine receptors in the subthalamic nucleus of normal and parkinsonian monkeys.

Authors:  Adriana Galvan; Xing Hu; Karen S Rommelfanger; Jean-Francois Pare; Zafar U Khan; Yoland Smith; Thomas Wichmann
Journal:  J Neurophysiol       Date:  2014-04-23       Impact factor: 2.714

5.  Differential degradation of motor deficits during gradual dopamine depletion with 6-hydroxydopamine in mice.

Authors:  A M Willard; R S Bouchard; A H Gittis
Journal:  Neuroscience       Date:  2015-06-09       Impact factor: 3.590

Review 6.  Pathological basal ganglia activity in movement disorders.

Authors:  T Wichmann; J O Dostrovsky
Journal:  Neuroscience       Date:  2011-06-22       Impact factor: 3.590

Review 7.  Basal ganglia activity patterns in parkinsonism and computational modeling of their downstream effects.

Authors:  Jonathan E Rubin; Cameron C McIntyre; Robert S Turner; Thomas Wichmann
Journal:  Eur J Neurosci       Date:  2012-07       Impact factor: 3.386

8.  Novel alternative splicing predicts a truncated isoform of the NMDA receptor subunit 1 (NR1) in embryonic rat brain.

Authors:  J M Campusano; M E Andrés; K Magendzo; J Abarca; L Tapia-Arancibia; G Bustos
Journal:  Neurochem Res       Date:  2005-04       Impact factor: 3.996

9.  Basal Ganglia circuits underlying the pathophysiology of levodopa-induced dyskinesia.

Authors:  Pedro Barroso-Chinea; Erwan Bezard
Journal:  Front Neuroanat       Date:  2010-09-14       Impact factor: 3.856

10.  Vulnerability of mesostriatal dopaminergic neurons in Parkinson's disease.

Authors:  Tomás González-Hernández; Ignacio Cruz-Muros; Domingo Afonso-Oramas; Josmar Salas-Hernandez; Javier Castro-Hernandez
Journal:  Front Neuroanat       Date:  2010-10-20       Impact factor: 3.856

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.